Glycobiology and Immunology

Carbohydrate-Based Vaccines and Immunotherapies

Volumn , Issue , 2008, Pages 1-53

  Aich, Udayanath ^a   Yarema, Kevin J ^a  

^a Johns Hopkins University   (United States)

Author keywords

Glycans three distinct roles in leukocyte extravasation; Glycobiology and immunology; Metabolic glycoengineering enhancing immunogenicity and therapeutic window

Indexed keywords

EID: 84889393217     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470473283.ch1     Document Type: Chapter

References (269)

1. Rademacher TW, Parekh RB, Dwek RA (1988) Glycobiology. Annu. Rev. Biochem. 57:785-838.
2. Morgan WTJ, Watkins WM (2000) Unravelling the biochemical basis of blood group ABO and Lewis antigenic specficity. Glycoconjug. J. 17:501-530.
3. Galili U (2005) The a-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol. Cell Biol. 83:674-686.
4. Martin MJ, Muotri A, Gage F, Varki A (2005) Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat. Med. 11:228-232.
5. Lowe JB (2003) Glycan-dependent leukocyte adhesion and recruitment in inflammation. Curr. Opin. Cell Biol. 15:531-538.
6. Horvat S, Jakas A (2004) Peptide and amino acid glycation: New insights into the Maillard reaction. J. Pept. Sci. 10:119-137.
7. McKillop AM, Abdel-Wahab YH, Mooney MH, O'Harte FP, Flatt PR (2002) Secretion of glycated insulin from pancreatic b-cells in diabetes represents a novel aspect of beta-cell dysfunction and glucose toxicity. Diabetes Metab. 28:3S61-63S69.
8. Turk Z, Ljubic S, Turk N, Benkov B (2001) Detection of auto antibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clin. Chim. Acta 303:105-115.
9. Dell A, Morris HR, Easton RL, Patankar M, Clark GF (1999) The glycobiology of gametes and fertilisation. Biochim. Biophys. Acta 1473:196-205.
10. Freeze HH (2001) Update and prespectives on congenital disorders of glycosylation. Glycobiology 11:129R-143R.
11. Keppler OT, Hinderlich S, Langner J, Schwartz-Albiez R, Reutter W, Pawlita M (1999) UDP-GlcNAc 2-epimerase: A regulator of cell surface sialylation. Science 284:1372-1376.
12. Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T, Barash M, Shemesh M, Sadeh M, Grabov-Nardin G, Shmilevich I, Friedmann A, Karpati G, Bradley WG, Baumbach L, Lancet D, Ben Asher E, Beckmann JS, Argov Z, Mitrani-Rosenbaum S (2001) The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat. Genet. 29:83-87.
13. Dennis JW, Pawling J, Cheung P, Partridge E, Demetriou M (2002) UDP-N-acetylglucosamine: a6-mannoside b1,6 N-acetylglucosaminyltransferase V (Mgat5) deficient mice. Biochim. Biophys. Acta 1573:414-422.
14. Dennis JW (1992) Changes in glycosylation associated with malignant transformation and tumor progression. In Fukuda M, Ed. Cell Surface Carbohydrates and Cell Development. CRC Press, Boca Raton, FL, pp. 161-194.
15. Dennis JW, Granovsky M, Warren CE (1999) Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1473:21-34.
16. Fuster MM, Esko JD (2005) The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat. Rev. Cancer 5:526-542.
17. Dube DH, Bertozzi CR (2005) Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 4:477-488.
18. Rudd PM, Endo T, Colominas C, Groth D, Wheeler SF, Harvey DJ, Wormald MR, Serban H, Prusiner SB, Kobata A, Dwek RA (1999) Glycosylation differences between the normal and pathogenic prion protein isoforms. Proc. Natl. Acad. Sci. U.S.A. 96: 13044-13049.
19. Endo T, Groth D, Prusiner SB, Kobata A (1989) Diversity of oligosaccharide structures linked to asparagines of the scrapie prion protein. Biochemistry 28:8380-8388.
20. Lawson VA, Collins SJ, Masters CL, Hill AF (2005) Prion protein glycosylation. J. Neurochem. 93:793-801.
21. Rudd PM, Merry AH, Wormald MR, Dwek RA (2002) Glycosylation and prion protein. Curr. Opin. Struct. Biol. 12:578-586.
22. Olsnes S (2004) The history of ricin, abrin and related toxins. Toxicon 44:361-370.
23. Sandvig K, Grimmer S, Iversen TG, Rodal K, Torgersen ML, Nicoziani P, van Deurs B (2000) Ricin transport into cells: Studies of endocytosis and intracellular transport. Int. J. Med. Microbiol. 290:415-420.
24. Suzuki Y, Ito T, Suzuki T, Holland J, Robert E, Chambers TM, Kiso M, Ishida H, Kawaoka Y (2000) Sialic acid species as a determinant of the host range of influenza A viruses. J. Virol. 74:11825-11831.
25. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y (2006) Avian flu: Influenza virus receptors in the human airway. Nature 440:435-436.
26. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA (2006) Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312:404-410.
27. Higa HH, Rogers GN, Paulson JC (1985) Influenza virus hemagglutinins differentiate between receptor determinants bearing N-acetyl-, N-glycolyl-, and N,O-diacetylneuraminic acids. Virology 144:279-282.
28. Thomas W, Forero M, Yakovenko O, Nilsson L, Vicini P, Sokurenko E, Vogel V (2006) Catch-bond model derived from allostery explains force-activated bacterial adhesion. Biophys. J. 90:753-764.
29. Nilsson LM, Thomas WE, Trintchina E, Vogel V, Sokurenko EV (2006) Catch bond-mediated adhesion without a shear threshold: Trimannose versus monomannose interactions with the FimH adhesin of Escherichia coli. J. Biol. Chem. 281:16656-16663.
30. Gabius H-J, Siebert H-C, André S, Jiménez-Barbero J, Rüdiger H (2004) Chemical biology of the sugar code. ChemBioChem 5:740-764.
31. Virji M, Evans D, Hadfield A, Grunert F, Teixeira AM,Watt SM (1999) Critical determinants of host receptor targeting by Neisseria meningitidis and Neisseria gonorrhoeae: Identification of Opa adhesiotopes on the N-domain of CD66 molecules. Mol. Microbiol. 34:538-551.
32. Kayano T, Burant CF, Fukumoto H, Gould GW, Fan YS, Eddy RL, Byers MG, Shows TB, Seino S, Bell GI (1990) Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNAs encoding an isoform (GLUT5) expressed in small instestine, kidney, muscle, and adipose tissue and an unusual glucose transporter pseudogene-like sequence (GLUT6). J. Biol. Chem. 265:13276-13282.
33. Wood IS, Trayhurn P (2003) Glucose transporters (GLUT and SGLT): Expanded families of sugar transport proteins. Br J. Nutr. 89:3-9.
34. Chen H, Wang Z, Sun Z, Kim EJ, Yarema KJ (2005) Mammalian glycosylation: An overview of carbohydrate biosynthesis. In Yarema KJ, Ed. Handbook of Carbohydrate Engineering. Francis & Taylor/CRC Press, Boca Raton, FL, pp. 1-48.
35. The Pubmed search engine and databases are available at: http://www.ncbi.nlm.nih.gov/sites/entrez?db1/4pubmed.
36. The KEGG (Kyoto Encyclopedia of Genes and Genomes) database is available at: http://www.genome.jp/kegg/.
37. The HUGO (Human Genome Organisation) database is available at: http://www.hugointernational.org/.
38. Campbell CT, Yarema KJ (2005) Large-scale approaches for glycobiology. Gen. Biol. 6:Article 236.
39. Bond MR, Kohler JJ (2007) Chemical methods for glycoprotein discovery. Curr. Opin. Chem. Biol. 11:52-58.
40. Tomiya N, Ailor E, Lawrence SM, Betenbaugh MJ, Lee YC (2001) Determination of nucleotides and sugar nucleotides involved in protein glycosylation by high-performance anion-exchange chromatography: Sugar nucleotide contents in cultured insect cells and mammalian cells. Anal. Biochem. 293:129-137.
41. Haslam SM, North SJ, Dell A (2006) Mass spectrometric analysis of N-and O-glycosylation of tissues and cells. Curr. Opin. Struct. Biol. 16:584-591.
42. Murrell MP, Yarema KJ, Levchenko A (2004) The systems biology of glycosylation. ChemBioChem 5:1334-1447.
43. Hossler P, Mulukutla BC, Hu W-S (2007) Systems analysis of N-glycan processing in mammalian cells. PLoS One 2:e713.
44. Krambeck FJ, Betenbaugh MJ (2005) A mathematical model of N-linked glycosylation. Biotechnol. Bioeng. 92:711-728.
45. Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, Dennis JW (2007) Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 129:123-134.
46. Hanover JA (2001) Glycan-dependent signaling: O-linked N-acetylglucosamine. FASEB J. 15:1865-1876.
47. Torres CR, Hart GW (1984) Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J. Biol. Chem. 259:3308-3317.
48. Zachara NE, Hart GW (2002) The emerging significance of O-GlcNAc in cellular regulation. Chem. Rev. 102:431-438.
49. TannerME (2005) The enzymes of sialic acid biosynthesis. Bioorg. Chem. 33:216-228.
50. Kayser H, Zeitler R, Kannicht C, Grunow D, Nuck R, Reutter W (1992) Biosynthesis of a nonphysiological sialic acid in different rat organs, using N-propanoyl-D-hexosamines as precursors. J. Biol. Chem. 267:16934-16938.
51. Campbell CT, Sampathkumar S-G,Weier C,Yarema KJ (2007) Metabolic oligosaccharide engineering: Perspectives, applications, and future directions. Mol. Biosyst. 3:187-194.
52. Gu J, Taniguchi N (2004) Regulation of integrin functions by N-glycans. Glycoconjug. J. 21:9-15.
53. Lanza F, Healy L, Sutherland DR (2001) Structural and functional features of the CD34 antigen: An update. J. Biol. Regul. Homeost. Agents 15:1-13.
54. Schachter H (1986) Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. Biochem. Cell. Biol. 64:163-181.
55. Rudd PM, Wormald MR, Wing DR, Prusiner SB, Dwek RA (2001) Prion glycoprotein: Structure, dynamics, and roles for the sugars. Biochemistry 40:3759-3766.
56. Ramsey T (1999) The number of people estimated to have ever lived was 96,100,000,000. Available at: http://www.math.hawaii.edu/~ramsey/People.html.
57. Spiro RG (2002) Protein glycosylation: Nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 12:43R-56R.
58. Kornfeld R, Kornfeld S (1985) Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54:631-664.
59. Rush JS, van Leyen K, Ouerfelli O, Wolucka B, Waechter CJ (1998) Transbilayer movement of Glc-P-dolichol and its function as a glucosyl donor: Protein-mediated transport of a water-soluble analog into sealed ER vesicles from pig brain. Glycobiology 8:1195-1205.
60. Rush JS, Gao N, Lehrman MA, Waechter CJ (2008) Recycling of dolichyl monophosphate to the cytoplasmic leaflet of the endoplasmic reticulum after the cleavage of dolichyl pyrophosphate on the lumenal monolayer. J. Biol. Chem. 283:4087-4093.
61. Tong L, Baskaran G, Jones MB, Rhee JK, Yarema KJ (2003) Glycosylation changes as markers for the diagnosis and treatment of human disease. In Harding S, Ed. Biochemical and Genetic Engineering Reviews. Intercept, Andover, Hampshire, UK, pp. 199-244.
62. Freeze HH, Aebi M (2005) Altered glycan structures: The molecular basis of congenital disorders of glycosylation. Curr. Opin. Struct. Biol. 15:490-498.
63. Lehle L, Strahl S, Tanner W (2006) Protein glycosylation, conserved from yeast to man: A model organism helps elucidate congenital human diseases. Angew. Chem. Int. Ed. Engl. 45:6801-6818.
64. Helenius A, Aebi M (2004) Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 73:1019-1049.
65. Aebi M, Hennet T (2001) Congenital disorders of glycosylation: Genetic model systems lead the way. Trends Cell Biol. 11:136-141.
66. Rush JS, Pannerselvam K, Waechter CJ, Freeze HH (2000) Mannose supplementation corrects GDP-mannose deficiency in cultured fibroblasts from some patients with congenital disorders of glycosylation (CDG). Glycobiology 10:829-835.
67. Helenius A, Aebi M (2001) Intracellular functions of N-linked glycans. Science 291:2364-2369.
68. Kato K, Kamiya Y (2007) Structural views of glycoprotein-fate determination in cells. Glycobiology 17:1031-1044.
69. Ruddock LW, Molinari M (2006) N-glycan processing in ER quality control. J. Cell Sci. 119:4373-4380.
70. Molinari M (2007) N-glycan structure dictates extension of protein folding or onset of disposal. Nat. Chem. Biol. 3:313-320.
71. Senger RS, Karim MN (2008) Prediction of N-linked glycan branching patterns using artificial neural networks. Math. Biosci. 211:89-104.
72. Peter-Katalinić J (2005) Methods in enzymology: O-glycosylation of proteins. Meth. Enzymol. 405:139-171.
73. Strous JG, Dekker J (1992) Mucin-type glycoproteins. Crit. Rev. Biochem. Mol. Biol. 27:57-92.
74. Ten Hagen KG, Fritz TA, Tabak LA (2003) All in the family: The UDPGalNAc: polypeptide N-acetylgalactosaminyltransferases. Glycobiology 13:1R-16R.
75. Brockhausen I, Schachter H (1997) Glycosyltransferases involved in N-and O-glycan biosynthesis. In Gabius HJ, Gabius S, (Eds.) Glycosciences: Status and Prespectives. Chapman and Hall, Weinheim, pp. 78-113.
76. Hang HC, Bertozzi CR (2005) The chemistry and biology of mucin-type O-linked glycosylation. Bioorg. Med. Chem. 13:5021-5034.
77. Hanover JA, Cohen CK, Willingham MC, Park MK (1987) O-linked N-acetylglucosamine is attached to proteins of the nuclear pore. Evidence for cytoplasmic and nucleoplasmic glycoproteins. J. Biol. Chem. 262:9887-9894.
78. Hart GW (1992) Glycosylation. Curr. Opin. Cell Biol. 4:1017-1023.
79. Heese-Peck A, Cole RN, Borkhsenious ON, Hart GW, Raikhel NV (1995) Plant nuclear pore complex proteins are modified by novel oligosaccharides with terminal N-acetylglucosamine. Plant Cell 7:1459-1471.
80. Zachara NE, Hart GW (2006) Cell signaling, the essential role of O-GlcNAc!. Biochim. Biophys. Acta 1761:599-617.
81. Freitas RA Jr (1999) Nanomedicine, Vol. I: Basic Capabilities. Landes Bioscience, Georgetown, TX.
82. Chester MA (1999) IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) Nomenclature of glycolipids: Recommendations 1997. Glycoconjug. J. 16:1-6.
83. Hakomori S (1981) Glycosphingolipids in cellular interaction, differentiation, and oncogenesis. Annu. Rev. Biochem. 50:733-764.
84. Yamashita T, Wada R, Sasaki T, Deng C, Bierfreund U, Sandhoff K, Proia RL (1999) A vital role for glycosphingolipid synthesis during development and differentiation. Proc. Natl. Acad. Sci. U.S.A. 96:9142-9147.
85. Allende ML, Proia RL (2002) Lubricating cell signaling pathways with gangliosides. Curr. Opin. Struct. Biol. 12:587-592.
86. Hakomori S-I (2002) The glycosynapse. Proc. Natl. Acad. Sci. U.S.A. 99:225-232.
87. Sprong H, Kruithof B, Leijendekker R, Slot JW, van Meer G, van der Sluijs P (1998) UDP-galactose:ceramide galactosyltransferase is a class I integral membrane protein of the endoplasmic reticulum. J. Biol. Chem. 273:25880-25888.
88. Marks DL, Wu K, Paul P, Kamisaka Y, Watanabe R, Pagano RE (1999) Oligomerization and topology of the Golgi membrane protein glucosylceramide synthase. J. Biol. Chem. 274:451-456.
89. Van Kaer L (2005) a-Galactosylceramide therapy for autoimmune diseases: Prospects and obstacles. Nat. Rev. Immunol. 5:31-42.
90. Bai J, Pagano RE (1997) Measurement of spontaneous transfer and transbilayermovement of BODIPY-labeled lipids in lipid vesicles. Biochemistry (Moscow) 36:8840-8848.
91. Lannert H, Gorgas K, Meissner I, Wieland FT, Jeckel D (1998) Functional organization of the Golgi apparatus in glycosphingolipid biosynthesis. Lactosylceramide and subsequent glycosphingolipids are formed in the lumen of the late Golgi. J. Biol. Chem. 273:2939-2946.
92. Nomura T, Takizawa M, Aoki J, Arai H, Inoue K,Wakisaka E, Yoshizuka N, Imokawa G, Dohmae N, Takio K, Hattori M, Matsuo N (1998) Purification, cDNA cloning, and expression of UDP-Gal: Glucosylceramide b1,4-galactosyltransferase from rat brain. J. Biol. Chem. 273:13570-13577.
93. Kolter T, Doering T, Wilkening G, Werth N, Sandhoff K (1999) Recent advances in the biochemistry of glycosphingolipid metabolism. Biochem. Soc. Trans. 27:409-415.
94. Fernandes Filho JA, Shapiro BE (2004) Tay-Sachs disease. Arch. Neurol. 61: 1466-1468.
95. Hakomori S, Kannagi R (1983) Glycosphingolipids as tumor-associated and differentiation markers. J. Natl. Cancer Inst. 71:231-251.
96. Hakomori S, Zhang Y (1997) Glycosphingolipid antigens and cancer therapy. Chem. Biol. 4:97-104.
97. Hakomori, S-I (1985) Aberrant glycosylation in cancer cell membranes as focused on glycolipids: Overview and perspectives. Cancer Res. 45:2405-2414.
98. Hakomori S-I (2002) Glycosylation defining cancer malignancy: New wine in an old bottle. Proc. Natl. Acad. Sci. U.S.A. 99:10231-10233.
99. Karlsson KA (1995) Microbial recognition of target-cell glycoconjugates. Curr. Opin. Struct. Biol. 5:622-635.
100. Low MG (1989) Glycosyl-phosphatidylinositol: A versatile anchor for cell surface proteins. FASEB J. 3:1600-1608.
101. Ferguson MA, Low MG, Cross GA (1985) Glycosyl-sn-1,2-dimyristylphosphatidylinositol is covalently linked to Trypnosoma brucei variant surface glycoprotein. J. Biol. Chem. 260:14547-14555.
102. Brewis IA, Ferguson MA, Mehlert A, Turner AJ, Hooper NM (1995) Structures of the glycosyl-phosphatidylinositol anchors of porcine and human renal membrane dipeptidase. Comprehensive structural studies on the porcine anchor and interspecies comparison of the glycan core structures. J. Biol. Chem. 270:22946-22956.
103. Hooper NM (1999) Detergent-insoluble glycosphingolipid/cholesterol-rich membrane domains, lipid rafts and caveolae. Mol. Membr. Biol. 16:145-156.
104. Ferguson MA (1992) Site of palmitoylation of a phospholipase C-resistant glycosylphosphatidylinositol membrane anchor. Biochem. J. 284:297-300.
105. Ferguson MA, Masterson WJ, Homans SW, McConville MJ (1992) GPI Membrane Anchors. Academic Press, San Diego.
106. Masterson WJ, Raper J, Doering TL, Hart GW, Englund PT (1990) Fatty acid remodeling: A novel reaction sequence in the biosynthesis of trypanosome glycosyl phosphatidylinositol membrane anchors. Cell 62:73-80.
107. Ferguson MA (1999) The structure, biosynthesis and functions of glycosylphosphatidylinositol anchors, and the contributions of trypanosome research. J. Cell Sci. 112:2799-2809.
108. Mansfield JM, Paulnock DM (2005) Regulation of innate and acquired immunity in African trypanosomiasis. Parasite Immunol. 27:361-371.
109. Häcker U, Nybakken K, Perrimon N (2005) Heparan sulphate proteoglycans: The sweet side of development. Nat. Rev. Mol. Cell Biol. 6:530-541.
110. Hodde JP, Badylak SF, Brightman AO, Voytik-Harbin SL (1996) Glycosaminoglycan content of small intestinal submucosa. Tiss. Eng. 2:209-217.
111. Pilarski LM, Pruski E,Wizniak J, Paine D, Seeberger K, Mant MJ, Brown CB, Belch AR (1999) Potential role for hyaluronan and the hyaluronan receptorRHAMMin mobilization and trafficking of hematopoietic progenitor cells. Blood 93:2918-2927.
112. Mummert ME (2005) Immunologic roles of hyaluronan. Immunol. Res. 31:189-206.
113. Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R, Bick RL (2004) Generic low-molecular-weight heparins: Some practical considerations. Semin. Thromb. Hemost. 30:703-713.
114. Freitas RA Jr (2003) Nanomedicine, Vol. IIA: Biocompatibility. Landes Bioscience, Georgetown, TX.
115. Litman GW, Cannon JP, Dishaw LJ (2005) Reconstructing immune phylogeny: New perspectives. Nat. Rev. Immunol. 5:866-879.
116. Hauton C, Smith VJ (2007) Adaptive immunity in invertebrates: A straw house without a mechanistic foundation. Bioessays 29:1138-1146.
117. Kawai T, Akira S (2006) Innate immune recognition of viral infection. Nat. Immunol. 7:131-137.
118. Le Y, Zhou Y, Iribarren P, Wang J (2004) Chemokines and chemokine receptors: Their manifold roles in homeostasis and disease. Cell. Mol. Immunol. 1:95-104.
119. Krishnaswamy G, Ajitawi O, Chi DS (2006) The human mast cell: An overview. Methods Mol. Biol. 315:13-34.
120. Weller PF, Lim K, Wan HC, Dvorak AM, Wong DT, Cruikshank WW, Kornfeld H, Center DM (1996) Role of the eosinophil in allergic reactions. Eur. Respir. J. Suppl. 22:109s-115s.
121. O'Connor GM, Hart OM, Gardiner CM (2006) Putting the natural killer cell in its place. Immunology 117:1-10.
122. Hsu KC, Dupont B (2005) Natural killer cell receptors: Regulating innate immune responses to hematologic malignancy. Semin. Hematol. 42:91-103.
123. Minakami R, Sumimotoa H (2006) Phagocytosis-coupled activation of the superoxideproducing phagocyte oxidase, a member of the NADPH oxidase (nox) family. Int. J. Hematol. 84:193-198.
124. Steinman RM (2001) Dendritic cells and the control of immunity: Enhancing the efficiency of antigen presentation. Mt. Sinai J. Med. 68:160-166.
125. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S (1999) Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1:362-368.
126. Siemasko K, Clark MR (2001) The control and facilitation of MHC class II antigen processing by the BCR. Curr. Opin. Immunol. 13:32-36.
127. Moser B, Ebert L (2003) Lymphocyte traffic control by chemokines: Follicular B helper T cells. Immunol. Lett. 85:105-112.
128. Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383:787-793.
129. Mercer JC, Ragin MJ, August A (2005) Natural killer T cells: Rapid responders controlling immunity and disease. Int. J. Biochem. Cell. Biol. 37:1337-1343.
130. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 5:147-159.
131. Rehder DS, Dillon TM, Pipes GD, Bondarenko PV (2006) Reversed-phase liquid chromatography/mass spectrometry analysis of reduced monoclonal antibodies in pharmaceutics. J. Chromatogr. A 1102:164-175.
132. Morrison SL (2005) The role of glycosylation in engineered antibodies. In Yarema K, Ed. Handbook of Carbohydrate Engineering. CRC Press (Taylor & Francis Group), Boca Raton, FL.
133. Yoo EM, Morrison SL (2005) IgA: An immune glycoprotein. Clin. Immunol. 116:3-10.
134. Burton DR, Woof JM (1992) Human antibody effector function. Adv. Immunol. 51:1-84.
135. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P (2003) Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325:979-989.
136. Jefferis R, Lund J, Pound JD (1998) IgG-Fc-mediated effector functions: Molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol. Rev. 163:59-76.
137. Wright A, Morrison SL (1997) Effect of glycosylation on antibody function: Implications for genetic engineering. Trends Biotechnol. 15:26-32.
138. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA (2007) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25:21-50.
139. Jefferis R, Lund J, Mizutani H, Nakagawa H, Kawazoe Y, Arata Y, Takahashi N (1990) A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem. J. 268:529-537.
140. Wormald MR, Rudd PM, Harvey DJ, Chang SC, Scragg IG Dwek RA (1997) Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 36:1370-1380.
141. Suzuki N, Khoo KH, Chen CM, Chen HC, Lee YC (2003) N-Glycan structures of pigeon IgG: A major serum glycoprotein containing Gala1-4 Gal termini. J. Biol. Chem. 278:46293-46306.
142. Hodoniczky J, Zheng YZ, James DC (2005) Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 21:1644-1652.
143. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complextype oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278:3466-3473.
144. Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670-673.
145. Miyahara S, Kiryu J, Miyamoto K, Katsuta H, Hirose F, Tamura H, Musashi K, Honda Y, Yoshimura N (2004) In vivo three-dimensional evaluation of leukocyte behavior in retinal microcirculation of mice. Invest. Ophthalmol. Vis. Sci. 45:4197-4201.
146. Weinbaum S, Zhang X, Han Y, Vink H, Cowin SC (2003) Mechanotransduction and flow across the endothelial glycocalyx. Proc. Natl. Acad. Sci. U.S.A. 100:7988-7995.
147. Weinbaum S, Tarbell JM, Damiano ER (2007) The structure and function of the endothelial glycocalyx layer. Annu. Rev. Biomed. Eng. 9:121-167.
148. Varki A (1994) Selectin ligands. Proc. Natl. Acad. Sci. U.S.A. 91:7390-7394.
149. Lou J, Zhu C (2007) A structure-based sliding-rebinding mechanism for catch bonds. Biophys. J. 92:1471-1485.
150. Zhu C, McEver RP (2005) Catch bonds: Physical models and biological functions. Mol. Cell. Biomech. 2:91-104.
151. Springer TA, Lasky LA (1991) Cell adhesion. Sticky sugars for selectins. Nature 349:196-197.
152. Puri KD, Chen S, Springer TA (1998) Modifying the mechanical property of and shear threshold of L-selectin adhesion independently of equilibrium properties. Nature 392:930-933.
153. Varki A (1997) Selectin ligands: Will the real ones please stand up? J. Clin. Invest. 99:158-162.
154. Bowman KG, Bertozzi CR (1999) Carbohydrate sulfotransferases: Mediators of extracellular communication. Chem. Biol. 6:R9-R22.
155. Bistrup A, Bhakta S, Lee JK, Belov YY, Gunn MD, Zuo F-R, Chiao-Chain H, Kannagi R, Rosen SD, Hemmerich S (1999) Sulfotransferases of two specificities function in the reconstitution of high endothelial cell ligands for L-selectin. J. Cell Biol. 145:899-910.
156. Kannagi R (2002) Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. Curr. Opin. Struct. Biol. 12:599-608.
157. Crocker PR (2002) Siglecs: Sialic acid-binding immunogloulin-like lectins in cell-cell interactions and signalling. Curr. Opin. Struct. Biol. 12:609-615.
158. Crocker PR, Varki A (2001) Siglecs in the immune system. Immunology 103:137-145.
159. Crocker PR, Gordon S (1986) Properties and distribution of a lectin-like hemagglutinin differentially expressed by murine stromal tissue macrophages. J. Exp. Med. 164:1862-1875.
160. Stamenkovic I, Seed B (1990) The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion. Nature 345:74-77.
161. Freeman SD, Kelm S, Barber EK, Crocker PR (1995) Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 85:2005-2012.
162. Sun J, Shaper NL, Itonori S, Heffer-Lauc M, Sheikh KA, Schnaar RL (2004) Myelinassociated glycoprotein (Siglec-4) expression is progressively and selectively decreased in the brains of mice lacking complex gangliosides. Glycobiology 14:851-857.
163. Angata T, Kerr SC, Greaves DR, Varki N, Crocker PR, Varki A (2002) Cloning and characterization of human Siglec-11. A recently evolved signaling that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia. J. Biol. Chem. 277:24466-24474.
164. Foussias G, Taylor SM, Yousef GM, Tropak MB, Ordon MH, Diamandis EP (2001) Cloning and molecular characterization of two splice variants of a new putative member of the Siglec-3-like subgroup of Siglecs. Biochem. Biophys. Res. Commun. 284:887-899.
165. Crocker PR, Varki A (2001) Siglecs, sialic acids, and innate immunity. Trends Immunol. 22:337-342.
166. Bakker TR, Piperi C, Davies EA, Merwe PA (2002) Comparison of CD22 binding to native CD45 and synthetic oligosaccharide. Eur. J. Immunol. 32:1924-1932.
167. Blixt O, Collins BE, van den Nieuwenhof IM, Crocker PR, Paulson JC (2003) Sialoside specificity of the siglec family assessed using novel multivalent probes: Identification of potent inhibitors of myelin-associated glycoprotein. J. Biol. Chem. 278:31007-31019.
168. Powell LD, Sgroi D, Sjoberg ER, Stamenkovic I, Varki A (1993) Natural ligands of the B cell adhesion molecule CD22 b carry N-linked oligosaccharides with b2,6-linked sialic acids that are required for recognition. J. Biol. Chem. 268:7019-7027.
169. Kelm S, Schauer R, Manuguerra JC, Gross HJ, Crocker PR (1994) Modifications of cell surface sialic acids modulate cell adhesion mediated by sialoadhesin and CD22. Glycoconjug. J. 11:576-585.
170. Bochner BS, Alvarez RA, Mehta P, Bovin NV, Blixt O, White JR, Schnaar RL (2005) Glycan array screening reveals a candidate ligand for Siglec-8. J. Biol. Chem. 280:4307-4312.
171. Brinkman-Van der Linden EC, Sjoberg ER, Juneja LR, Crocker PR, Varki N, Varki A (2000) Loss of N-glycolylneuraminic acid in human evolution. Implications for sialic acid recognition by siglecs. J. Biol. Chem. 275:8633-8640.
172. Sonnenburg JL, Altheide TK, Varki A (2004) A uniquely human consequence of domain-specific functional adaptation in a sialic acid-binding receptor. Glycobiology 14:339-346.
173. Tateno H, Crocker PR, Paulson JC (2005) Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 60-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology 15: 1125-1135.
174. Campanero-Rhodes MA, Childs RA, Kiso M, Komba S, Le Narvor C, Warren J, Otto D, Crocker PR, Feizi T (2006) Carbohydrate microarrays reveal sulphation as a modulator of siglec binding. Biochem. Biophys. Res. Commun. 344:1141-1146.
175. Rapoport EM, Pazynina GV, Sablina MA, Crocker PR, Bovin NV (2006) Probing sialic acid binding Ig-like lectins (siglecs) with sulfated oligosaccharides. Biochemistry (Moscow) 71:496-504.
176. Collins BE, Blixt O, DeSieno AR, Bovin N, Marth JD, Paulson JC (2004) Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc. Natl. Acad. Sci. U.S.A. 101:6104-6109.
177. Hanasaki K, Varki A, Powell LD (1995) CD22-mediated cell adhesion to cytokineactivated human endothelial cells. Positive and negative regulation by a2,6-sialylation of cellular glycoproteins. J. Biol. Chem. 270:7533-7542.
178. Razi N, Varki A (1998) Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B-lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 95:7469-7474.
179. Razi N, Varki A (1999) Cryptic sialic acid binding lectins on human blood leukocytes can be unmasked by sialidase treatment or cellular activation. Glycobiology 9:1225-1234.
180. Han S, Collins BE, Bengtson P, Paulson JC (2005) Homo-multimeric complexes of CD22 revealed by in situ photoaffinity protein-glycan crosslinking. Nat. Chem. Biol. 1:93-97.
181. Lanoue A, Batista FD, Stewart M, Neuberger MS (2002) Interaction of CD22 with a-2,6-linked sialoglycoconjugates: Innate recognition of self to dampen B cell autoreactivity?. Eur. J. Immunol. 32:348-355.
182. Falco M, Biassoni R, Bottino C, Vitale M, Sivori S, Augugliaro R, Moretta L, Moretta A (1999) Identification and molecular cloning of 75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. J. Exp. Med. 190:793-802.
183. Nicoll G, Ni J, Liu D, Klenerman P, Munday J, Dubock S, Mattei MG, Crocker PR (1999) Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J. Biol. Chem. 274:34089-34095.
184. Avril T, North SJ, Haslam SM, Willison HJ, Crocker PR (2006) Probing the cis interactions of the inhibitory receptor Siglec-7 with a2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of a-2,8-sialyltransferase gene expression. J. Leukoc. Biol. 80:787-796.
185. Nicoll G, Avril T, Lock K, Furukawa K, Bovin N, Crocker PR (2003) Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and-independent mechanisms. Eur. J. Immunol. 33:1642-1648.
186. Lundquist JJ, Toone EJ (2002) The cluster glycoside effect. Chem. Rev. 102:555-578.
187. Kiessling LL, Pohl S (1996) Strength in numbers: Non-natural polyvalent carbohydrate derivatives. Chem. Biol. 3:71-77.
188. Yamamoto F, Hakomori S (1990) Sugar-nucleotide donor specificity of histo-blood group A and B transferases is based on amino acid substitutions. J. Biol. Chem. 265:19257-19262.
189. Chen X, Andreana PR, Wang PG (1999) Carbohydrates in transplantation. Curr. Opin. Chem. Biol. 3:650-658.
190. Yarema KJ, Bertozzi CR (1998) Chemical approaches to glycobiology and emerging carbohydrate-based therapeutic agents. Curr. Opin. Chem. Biol. 2:49-61.
191. Galili U (2001) The a-gal epitope (Gala1-3Galb1-4GlcNAc-R) in xenotransplantation. Biochimie 83:557-563.
192. Galili U (2004) Immune response, accommodation, and tolerance to transplantation carbohydrate antigens. Transplantation 78:1093-1098.
193. Ramssondar JJ, Macháty Z, Costa C, Williams BL, Fodor WL, Bondioli KR (2003) Production of a1,3-galactosyltransferase-knockout cloned pigs expressing human a1,2-fucosylosyltransferase. Biol. Reprod. 69:437-445.
194. Dai Y, Vaught TD, Boone J, Chen S-H, Phelps CJ, Ball S, Monahan JA, Jobst PM, McCreath KJ, Lamborn AE, Cowell-Lucero JL, Wells KD, Colman A, Polejaeva IA, Ayares DL (2002) Targeted disruption of the a1,3-galactosyltransferase gene in cloned pigs. Nat. Biotechnol. 20:251-255.
195. Milland J, Christiansen D, Sandrin MS (2005) a1,3-Galactosyltransferase knockout pigs are available for xenotransplantation: Are glycosyltransferases still relevant? Immunol. Cell Biol. 83:687-693.
196. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, Muchmore E (2003) Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. U.S.A. 100:12045-12050.
197. Malykh YN, Schauer R, Shaw L (2001) N-Glycolylneuraminic acid in human tumours. Biochimie 83:623-634.
198. Franco A (2008) Glycoconjugates as vaccines for cancer immunotherapy: Clinical trials and future directions. Anticancer Agents Med. Chem. 8:86-91.
199. Reiman JM, Kmieciak M, Manjili MH, Knutson KL (2007) Tumor immunoediting and immunosculpting pathways to cancer progression. Semin. Cancer Biol. 17:275-287.
200. Jakóbisiak M, Lasek W, Gołab J (2003) Natural mechanisms protecting against cancer. Immunol. Lett. 90:103-122.
201. Sell S (1990) Cancer-associated carbohydrates identified by monoclonal antibodies. Hum. Pathol. 21:1003-1019.
202. Hakomori S (1991) Possible functions of tumor-associated carbohydrate antigens. Curr. Opin. Immunol. 3:646-653.
203. Singhal A, Hakomori S (1990) Molecular changes in carbohydrate antigens associated with cancer. Bioessays 12:223-230.
204. Burchell JM, Mungul A, Taylor-Papadimitiou J (2001) O-Linked glycosylation in the mammary gland: Changes that occur during malignancy. J. Mammary Gland Biol. Neoplasia 6:355-364.
205. Brockhausen I (1999) Pathways of O-glycan biosynthesis in cancer cells. Biochim. Biophys. Acta 1473:67-95.
206. Brockhausen I (2003) Glycodynamics of mucin biosynthesis in gastrointestinal tumor cells. Adv. Exp. Med. Biol. 535:163-188.
207. Brockhausen I (2003) Sulphotransferases acting on mucin-type oligosaccharides. Biochem. Soc. Trans. 31:318-325.
208. Nilsson O, Brezicka FT, Holmgren J, Sörenson S, Svennerholm L, Yngvason F, Lindholm L (1986) Detection of a ganglioside antigen associated with small cell lung carcinomas using monoclonal antibodies directed against fucosyl-GM1. Cancer Res. 46:1403-1407.
209. Brezicka FT, Olling S, Nilsson O, Bergh J, Holmgren J, Sörenson S, Yngvason F, Lindholm L (1989) Immunohistological detection of fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies. Cancer Res. 49:1300-1305.
210. Vangsted AJ, Clausen H, Kjeldsen TB, White T, Sweeney B, Hakomori S, Drivsholm L, Zeuthen J (1991) Immunochemical detection of a small cell lung cancer-associated ganglioside (FucGM1) antigen in serum. Cancer Res. 51:2879-2884.
211. Brezicka T, Bergman B, Olling S, Fredman P (2000) Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues. Lung Cancer 28:29-36.
212. Galili U (2004) Autologous tumor vaccines processed to express a-gal epitopes: A practical approach to immunotherapy in cancer. Cancer Immunol. Immunother. 53:935-945.
213. McCarty OJT, Mousa SA, Bray PF, Konstantopoulos K (2000) Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood 96:1789-1797.
214. Bengoechea JA, Najdenski H, Skurnik M (2004) Lipopolysaccharide O antigen status of Yersinia enterocolitica O:8 is essential for virulence and absence of O antigen affects the expression of other Yersinia virulence factors. Mol. Microbiol. 52:451-569.
215. Bruneteau M, Minka S (2003) Lipopolysaccharides of bacterial pathogens from the genus Yersinia: A mini-review. Biochimie 85:145-152.
216. Pier GB (2003) Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen. Carbohydr. Res. 338:2549-2556.
217. Vliegenthart JFG (2006) Carbohydrate based vaccines. FEBS Lett. 580:2945-2950.
218. AlonsoDeVelasco E, Verheul AF, Verhoef J, Snippe H (1995) Streptococcus pneumoniae: Virulence factors, pathogenesis, and vaccines. Microbiol. Rev. 59:591-603.
219. Seeberger PH, Werz DB (2005) Automated synthesis of oligosaccharides as a basis for drug discovery, Nat. Rev. Drug Discov. 4:751-763.
220. Beyene A, Basu A, Meyer K, Ray R (2004) Influence of N-linked glycans on intracellular transport of hepatitis C virus E1 chimeric glycoprotein and its role in pseudotype virus infectivity. Virology 324:273-285.
221. Eichler R, Lenz O, GartenW, Strecker T (2006) The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein G.P.-C. Virol. J. 3:41.
222. Aguilar HC, Matreyek KA, Filone CM, Hashimi ST, Levroney EL, Negrete OA, Bertolotti-Ciarlet A, Choi DY, McHardy I, Fulcher JA, Su SV, Wolf MC, Kohatsu L, Baum LG, Lee B (2006) N-Glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J. Virol. 80:4878-4889.
223. Melanson VR, Iorio RM (2006) Addition of N-glycans in the stalk of the Newcastle disease virus HN protein blocks its interaction with the F protein and prevents fusion. J. Virol. 80:623-633.
224. Shi X, Brauburger K, Elliott RM (2005) Role of N-linked glycans on bunyamwera virus glycoproteins in intracellular trafficking, protein folding, and virus infectivity. J. Virol. 79:13725-13734.
225. Moll M, Kaufmann A, Maisner A (2004) Influence of N-glycans on processing and biological activity of the nipah virus fusion protein. J. Virol. 78:7274-7278.
226. Lin G, Simmons G, Pöhlmann S, Baribaud F, Ni H, Leslie GJ, Haggarty BS, Bates P, Weissman D, Hoxie JA, Doms RW (2003) Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J. Virol. 77:1337-1346.
227. Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, Patch JR, Choudhary A, Wang LF, Eaton BT, Broder CC (2005) Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J. Virol. 79:6690-6702.
228. Oostra M, de Haan CA, de Groot RJ, Rottier PJ (2006) Glycosylation of the severe acute respiratory syndrome coronavirus triple-spanning membrane proteins 3a and M. J. Virol. 80:2326-2336.
229. Schowalter RM, Smith SE, Dutch RE (2006) Characterization of human metapneumovirus F protein-promoted membrane fusion: Critical roles for proteolytic processing and low pH. J. Virol. 80:10931-10941.
230. Shirato K, Miyoshi H, Goto A, Ako Y, Ueki T, Kariwa H, Takashima I (2004) Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. J. Gen. Virol. 85:3637-3645.
231. Scherret JH, Mackenzie JS, Khromykh AA, Hall RA (2001) Biological significance of glycosylation of the envelope protein of Kunjin virus. Ann. N.Y. Acad. Sci. 951:361-362.
232. Beasley DW, Whiteman MC, Zhang S, Huang CY, Schneider BS, Smith DR, Gromowski GD, Higgs S, Kinney RM, Barrett AD (2005) Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J. Virol. 79:8339-8347.
233. Lad VJ, Shende VR, Gupta AK, Koshy AA, Roy A (2000) Effect of tunicamycin on expression of epitopes on Japanese encephalitis virus glycoprotein E in porcine kidney cells. Acta Virol. 44:359-364.
234. Wagner R,Wolff T, Herwig A, Pleschka S, Klenk HD (2000) Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: A study by reverse genetics. J. Virol. 74:6316-6323.
235. Klenk HD, Wagner R, Heuer D, Wolff T (2002) Importance of hemagglutinin glycosylation for the biological functions of influenza virus. Virus Res. 82:73-75.
236. Baigent SJ, McCauley JW (2001) Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture. Virus Res. 79:177-185.
237. Daniels R, Kurowski B, Johnson AE, Hebert DN (2003) N-Linked glycans direct the cotranslational folding pathway of influenza hemagglutinin. Mol. Cell 11:79-90.
238. Fenouillet E, Gluckman JC, Bahraoui E (1990) Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1. J. Virol. 64:2841-2848.
239. Montefiori DC, Robinson WEJ, Mitchell WM (1988) Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 85:9248-9252.
240. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V (2001) Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58:19-42.
241. Sagar M, Wu X, Lee S, Overbaugh J (2006) Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80:9586-9598.
242. Wolk T, Schreiber M (2006) N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med. Microbiol. Immunol. 195:165-172.
243. Tzianabos A, Wang JY, Kasper DL (2003) Biological chemistry of immunomodulation by zwitterionic polysaccharides. Carbohydr. Res. 338:2531-2538.
244. González-Fernández M, Carrasco-Marín E, Alvarez-Domínguez C, Outschoorn IM, Leyva-Cobián F (1997) Inhibitory effects of thymus-independent type 2 antigens on MHC class II-restricted antigen presentation: Comparative analysis of carbohydrate structures and the antigen presenting cell. Cell. Immunol. 176:1-13.
245. Hirst RA, Kadioglu A, O'callaghan C, Andrew PW (2004) The role of pneumolysin in pneumococcal pneumonia and meningiti. Clin. Exp. Immunol. 138: 246.
246. Lombard M, Pastoret PP, Moulin AM (2007) A brief history of vaccines and vaccination. Rev. Sci. Tech. 26:29-48.
247. Borman S (2004) Carbohydrate vaccines. Chem. Eng. News 82:31-35.
248. Jennings HJ (1983) Capsular polysaccharides as human vaccines. Adv. Carbohydr. Chem. Biochem. 41:155-208.
249. Warren JD, Geng X, Danishefsky SJ (2006) Synthetic glycopeptide-based vaccines. Top. Curr. Chem. 267:109-141.
250. Wang Q, Zhang J, Guo Z (2007) Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell. Bioorg. Med. Chem. 15:7561-7567.
251. Allen JR, Allen JG, Zhang XF, Williams LJ, Zatorski A, Ragupathi G, Livingston PO, Danishefsky SJ (2000) A second generation synthesis of the MBr1 (Globo-H) breast tumor antigen: New application of the N-pentenyl glycoside method for achieving complex carbohydrate protein linkages. Chemistry 6:1366-1375.
252. Deshpande PP, Danishefsky SJ (1997) Total synthesis of the potential anticancer vaccine KH-1 adenocarcinoma antigen. Nature 387:164-166.
253. Allen JR, Harris CR, Danishefsky SJ (2001) Pursuit of optimal carbohydrate-based anticancer vaccines: Preparation of a multiantigenic unimolecular glycopeptide containing the Tn, MBr1, and LewisY antigens. J. Am. Chem. Soc. 123:1890-1897.
254. Seeberger PH (2003) Automated carbohydrate synthesis to drive chemical glycomics. Chem. Commun. 21:1115-1121.
255. Seeberger PH, Werz DB (2007) Synthesis and medical applications of oligosaccharides. Nature 446:1046-1051.
256. Koeller KM,Wong CH (2000) Complex carbohydrate synthesis tools for glycobiologists: Enzyme-based approach and programmable one-pot strategies. Glycobiology 10:1157-1169.
257. Koeller KM,Wong C-H (2000) Synthesis of complex carbohydrates and glycoconjugates: Enzyme-based and programmable one-pot strategies. Chem. Rev. 100:4465-4494.
258. Ragupathi G, Koide F, Livingston PO, Cho YS, Endo A, Wan Q, Spassova MK, Keding SJ, Allen J, Ouerfelli O, Wilson RM, Danishefsky SJ (2006) Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: A synthetic route to anticancer vaccine candidates. J. Am. Chem. Soc. 128:2715-2725.
259. Oetke C, Brossmer R, Mantey LR, Hinderlich S, Isecke R, Reutter W, Keppler OT, Pawlita M (2002) Versatile biosynthetic engineering of sialic acid in living cells using synthetic sialic acid analogues. J. Biol. Chem. 277:6688-6695.
260. Bardor M, Nguyen DH, Diaz S, Varki A (2005) Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J. Biol. Chem. 280:4228-4237.
261. Liu T, Guo Z, Yang Q, Sad S, Jennings HJ (2000) Biochemical engineering of surface a2,8 polysialic acid for immunotargeting tumor cells. J. Biol. Chem. 275:32832-32836.
262. Hayrinen J, Jennings H, Raff HV, Rougon G, Hanai N, Gerardy-Schahn R, Finne J (1995) Antibodies to polysialic acid and its N-propyl derivative: Binding properties and interaction with human embryonal brain glycopeptides. J. Infect. Dis. 171:1481-1490.
263. Chefalo P, Pan Y, Nagy N, Guo Z, Harding CV (2006) Efficient metabolic engineering of GM3 on tumor cells by N-phenylacetyl-D-mannosamine. Biochemistry 45:3733-3739.
264. Chefalo P, Pan Y-B, Nagy N, Harding C, Guo Z-W (2004) Preparation and immunological studies of protein conjugates of N-acylneuraminic acids. Glycoconjug. J. 20:407-414.
265. Schilling B, Goon S, Samuels NM, Gaucher SP, Leary JA, Bertozzi CR, Gibson BW (2001) Biosynthesis of sialylated lipooligosaccharides in Haemophilus ducreyi is dependent on exogenous sialic acid and not mannosamin. Incorporation studies using N-acylmannosamine analogues, N-Glycolylneuraminic acid, and 13C-labeled N-acetylneuraminic acid. Biochemistry 40:12666-12677.
266. Goon S, Schilling B, Tullius MV, Gibson BW, Bertozzi CR (2003) Metabolic incorporation of unnatural sialic acids into Haemophilus ducreyi lipooligosaccharides. Proc. Natl. Acad. Sci. U.S.A. 18:3089-3094.
267. Verez-Bencomo V, Fernández-Santana V, Hardy E, Toledo ME, Rodríguez MC, Heynngnezz L, Rodriguez A, Baly A, Herrera L, Izquierdo M, Villar A, Valdés Y, Cosme K, Deler ML, Montane M, Garcia E, Ramos A, Aguilar A, Medina E, Toraño G, Sosa I, Hernandez I, Martínez R, Muzachio A, Carmenates A, Costa L, Cardoso F, Campa C, Diaz M, Roy R (2004) A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305:522-525.
268. Kaiser J (2004) Synthetic vaccine is a sweet victory for Cuban science. Science 305:460.
269. Ingale S,Wolfert MA, Gaekwad J, Buskas T, Boons G-J (2007) Robust immune responses elicited by a fully synthetic three-component vaccine. Nat. Chem. Biol. 3:663-667.